Personalized ctDNA for Monitoring Disease Status in Head and Neck Squamous Cell Carcinoma
Glenn J. Hanna(Dana-Farber Cancer Institute), Eleni M. Rettig(Dana-Farber Cancer Institute), Jonathan D. Schoenfeld(Brigham and Women's Hospital), Ravindra Uppaluri(Dana-Farber Cancer Institute), Laura A. Goguen(Brigham and Women's Hospital), Donald J. Annino(Harvard University), Kartik Sehgal(Beth Israel Deaconess Medical Center), Michelle S. Mullin(Harvard University), Roy B. Tishler(Dana-Farber Cancer Institute), Danielle N. Margalit(Harvard University), Robert I. Haddad(Georgetown University), Rosh K.V. Sethi(Brigham and Women's Hospital), Nicole Scarfo(Harvard University), Michael J. Dennis(University of San Diego)
Cited by 48
Related Papers
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
|New England Journal of Medicine|2016|5.1k
Cisplatin and Fluorouracil Alone or with Docetaxel in Head and Neck Cancer
|New England Journal of Medicine|2007|1.7k
Head and Neck Cancers, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
|Journal of the National Comprehensive Cancer Network|2020|1.4k
Recent Advances in Head and Neck Cancer
|New England Journal of Medicine|2008|926